162 related articles for article (PubMed ID: 9415265)
41. Current diagnosis of acromegaly.
Cordero RA; Barkan AL
Rev Endocr Metab Disord; 2008 Mar; 9(1):13-9. PubMed ID: 18236162
[TBL] [Abstract][Full Text] [Related]
42. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
43. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
44. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
Ezzat S; Redelmeier DA; Gnehm M; Harris AG
J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
[TBL] [Abstract][Full Text] [Related]
45. Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.
Duan L; Zhu H; Xing B; Gu F
BMC Endocr Disord; 2017 Sep; 17(1):55. PubMed ID: 28874187
[TBL] [Abstract][Full Text] [Related]
46. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
47. Advances in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. Participants of the "Conference on Medical and Surgical Treatment of Pituitary Adenomas" (Zürich, 5th October, 1991).
Fahlbusch R; Giovanelli M; Buchfelder M; Losa M
J Endocrinol Invest; 1993 Jun; 16(6):449-60. PubMed ID: 8370920
[No Abstract] [Full Text] [Related]
48. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
49. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates.
Losa M; Mortini P; Urbaz L; Ribotto P; Castrignanó T; Giovanelli M
J Neurosurg; 2006 Jun; 104(6):899-906. PubMed ID: 16776333
[TBL] [Abstract][Full Text] [Related]
50. Somatostatin analogs: their role in the treatment of growth hormone hypersecretion and excessive body growth.
Lamberts SW
Growth Regul; 1991 Mar; 1(1):3-10. PubMed ID: 1688186
[No Abstract] [Full Text] [Related]
51. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
[TBL] [Abstract][Full Text] [Related]
52. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
53. A case and review of acromegaly-induced cardiomyopathy and the relationship between growth hormone and heart failure: cause or cure or neither or both?
Schwarz ER; Jammula P; Gupta R; Rosanio S
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):232-44. PubMed ID: 17220469
[TBL] [Abstract][Full Text] [Related]
54. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
55. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.
Bogazzi F; Di Bello V; Palagi C; Donne MG; Di Cori A; Gavioli S; Talini E; Cosci C; Sardella C; Brogioni S; Mariani M; Martino E
Clin Endocrinol (Oxf); 2005 May; 62(5):590-6. PubMed ID: 15853830
[TBL] [Abstract][Full Text] [Related]
56. Headache in acromegaly: dramatic improvement with the somatostatin analogue SMS 201-995.
Musolino NR; Marino Júnior R; Bronstein MD
Clin J Pain; 1990 Sep; 6(3):243-5. PubMed ID: 2135020
[TBL] [Abstract][Full Text] [Related]
57. Acute liver injury and octreotide.
González-Martín JA; Donnay S; Morillas J; Gómez-Aparicio C; Garcia-Cano J; Pérez-Vigara G; Roldán A
Am J Gastroenterol; 1996 Nov; 91(11):2434-5. PubMed ID: 8931436
[TBL] [Abstract][Full Text] [Related]
58. Acromegaly and primary amenorrhea: ovulation and pregnancy induced by SMS 201-995 and bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Piolini R; Camboni MG
J Endocrinol Invest; 1990 Feb; 13(2):193. PubMed ID: 2329262
[No Abstract] [Full Text] [Related]
59. Chromophobe pituitary adenoma with acromegaly and TSH-induced hyperthyroidism associated with parathyroid adenoma. Acromegaly and parathyroid adenoma.
Lamberg BA; Ripatti J; Gordin A; Juustila H; Sivula A; af Björkesten G
Acta Endocrinol (Copenh); 1969 Jan; 60(1):157-72. PubMed ID: 4308288
[No Abstract] [Full Text] [Related]
60. Controversy: radiotherapy for acromegaly.
Thorner MO
Clin Endocrinol (Oxf); 2003 Feb; 58(2):136-7. PubMed ID: 12580926
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
